Clindamycin Phosphate 10 mg/mL Gel
Other active recalls for Clindamycin Phosphate (different manufacturers) — 6 · tap to view
🆔 Identity & classification
Where does this data come from?
🏷️ RxNorm drug class
This medicine belongs to the Lincosamide Antibacterial class.
Where does this data come from?
🏭 Manufacturer & labeler
Where does this data come from?
🩺 Clinical
Topical clindamycin is used to treat acne. Clindamycin is in a class of medications called lincomycin antibiotics. It works by slowing or stopping the growth of bacteria that cause acne and by decreasing swelling.
Read the full MedlinePlus article ↗- Clindamycin is used for serious bacterial infections — things like deep skin infections, lung abscesses, pelvic infections, and abdominal infections. It's often chosen when penicil...
- What kinds of infections is clindamycin actually used for?
- You don't have to eat with it — food doesn't meaningfully change how it's absorbed. But the most important thing is to take each capsule with a full, large glass of water, and stay...
- Do I need to take clindamycin with food?
Patient education
Supplement & herbal interactions
Clindamycin may be associated with lower levels of 7 nutrients — worth a chat with your pharmacist, not a cause for alarm.
Where does this data come from?
Ask a licensed pharmacist directly — free, answered by our team.
🧪 Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.
-
UNII F68VH75CJC
A synthetic polymer made from acrylic acid that thickens and stabilizes liquid or gel formulations. It's used as a gelling agent and emulsifier to create the desired texture and consistency in topical medicines.
-
UNII A2I8C7HI9T
Methylparaben is a preservative derived from benzoic acid that prevents growth of bacteria, fungi, and mold in medicines. It extends the product's shelf life and maintains safety during storage.
-
UNII B697894SGQ
Polyethylene glycol 400 is a clear, thick liquid made from petroleum-derived polymers. It acts as a solvent and humectant in medicines, helping dissolve active ingredients and retain moisture in the formulation.
-
UNII 6DC9Q167V3
Propylene glycol is a clear liquid derived from petroleum or vegetable sources. It acts as a solvent, humectant, and preservative in medicines, helping dissolve active ingredients and maintain product stability.
-
UNII 55X04QC32I
A strong alkaline chemical used to adjust and maintain the pH balance of liquid medicines. It helps keep the medicine stable and ensures it stays effective during storage.
-
UNII 059QF0KO0R
Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.
6 inactive ingredients listed in the exact product block matched to this NDC.
Where does this data come from?
ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
💲 Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per mL | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | $5.280 | $396.02 / 75 ml |
| Medicaid paysCMS SDUD · 12 mo | $6.37 | $478.07 / 75 ml |
| Medicare drug plans payPart D · Q2 2026 | $6.30 | $472.52 / 75 ml |
Where does this data come from?
🔁 Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Clindamycin Phosphate 10 mg/mL 51672-1400-04 | Sun | 1 bottle | $0.261 | AB | Availability likely | save 95% |
| clindamycin phosphate 10 mg/mL 00168-0203-60 | E. | 1 bottle | $0.261 | AB | Availability likely | save 95% |
| Clindamycin Phosphate 10 mg/mL 45802-0128-01 | Padagis | 60 ml | $0.261 | AB | Availability likely | save 95% |
| clindamycin phosphate 10 mg/mL 59762-3744-01 | Mylan | 1 bottle | $0.261 | AB | Availability likely | save 95% |
| Cleocin T 10 mg/mL 00009-3329-01 | Pharmacia | 1 bottle | $0.465 | AB | FDA listed | save 91% |
| Clindamycin Phosphate 1 g/100mL 69238-2031-07 | Amneal | 1 bottle | $3.481 | AB2 | Availability likely | save 34% |
| Clindamycin Phosphate 1 g/10mL 73473-0302-75 | Solaris | 1 bottle | $3.481 | AB2 | Availability likely | save 34% |
| Clindamycin Phosphate 10 mg/mLthis 68682-0462-75 | Oceanside | 1 bottle | $5.280 | AB2 | FDA listed | — |
| Clindagel 10 mg/mL 16781-0462-06 | Bausch | 6 bottles | — | AB2 | FDA listed | — |
| Clindamycin Phosphate 10 mg/mL 63629-9459-01 | Bryant | 60 ml | — | AB | FDA listed | — |
| clindamycin phosphate 10 mg/mL 72162-2147-06 | Bryant | 1 bottle | — | AB | FDA listed | — |
| Clindamycin Phosphate 10 mg/mL 63629-8632-01 | Bryant | 60 ml | — | AB | FDA listed | — |
| Clindamycin Phosphate 10 mg/mL 71335-2953-01 | Bryant | 60 ml | — | AB | FDA listed | — |
| Clindamycin Phosphate 10 mg/mL 72162-1395-06 | Bryant | 60 ml | — | AB | FDA listed | — |
Where does this data come from?
⏳ Availability & generic status
FDA-approved generic versions are listed, and recent pricing/market data suggests they may be available — see Therapeutic equivalents.
Where does this data come from?
🗺️ Medicaid utilization & spend
📊 Medicare Part D spend CMS · PART D · 2026 (Q1)
🔬 Reported adverse events (FAERS)
Top reported reactions
Age at onset
Reporter sex
Serious outcomes
Where does this data come from?
📦 Packaging — all sizes for this product
| Package NDC | Description | Marketing start | Status |
|---|---|---|---|
| 68682-0462-75 You're viewing this | 1 BOTTLE in 1 CARTON (68682-462-75) / 75 mL in 1 BOTTLE | 2018-06-08 | Active |
📄 Full prescribing information FDA SPL
🎯 Indications and Usage ▾
CLINICAL STUDIES In one 12-week multicenter, randomized, evaluator-blind, vehicle-controlled, parallel comparison clinical trial in which patients used Clindamycin Phosphate Topical Gel, 1%, once daily or the vehicle gel once daily, in the treatment of acne vulgaris of mild to moderate severity, Clindamycin Phosphate Topical Gel applied once daily was more effective than the vehicle applied once daily. The mean percent reductions in lesion counts at the end of treatment in this study are shown in the following table: Lesions Clindamycin Phosphate Topical Gel QD N=162 Vehicle Gel QD N=82 Inflammatory 51% 40% P<0.05 Noninflammatory 25% 12% Total 38% 27% There was a trend in the investigator’s global assessment of the results, which favored Clindamycin Phosphate Topical Gel QD over the vehicle QD.
In a contact sensitization study, four of the 200 subjects appeared to develop suggestive evidence of allergic contact sensitization to Clindamycin Phosphate Topical Gel. There was no signal for contact sensitization in the clinical trials under normal use conditions.
⏱️ Dosage and Administration ▾
DOSAGE AND ADMINISTRATION Apply a thin film of Clindamycin Phosphate Topical Gel once daily to the skin where acne lesions appear. Use enough to cover the entire affected area lightly. Keep container tightly closed.
⛔ Contraindications ▾
CONTRAINDICATIONS Clindamycin Phosphate Topical Gel is contraindicated in individuals with a history of hypersensitivity to preparations containing clindamycin or lincomycin, a history of regional enteritis or ulcerative colitis, or a history of antibiotic-associated colitis.
⚠️ Warnings ▾
WARNINGS Orally and parenterally administered clindamycin has been associated with severe colitis, which may result in patient death. Use of the topical formulation of clindamycin results in absorption of the antibiotic from the skin surface. Diarrhea, bloody diarrhea, and colitis (including pseudomembranous colitis) have been reported with the use of topical and systemic clindamycin.
Studies indicate a toxin(s) produced by Clostridia is one primary cause of antibiotic-associated colitis. The colitis is usually characterized by severe persistent diarrhea and severe abdominal cramps and may be associated with the passage of blood and mucus. Endoscopic examination may reveal pseudomembranous colitis.
Stool culture for Clostridium difficile and stool assay for C. difficile toxin may be helpful diagnostically. When significant diarrhea occurs, the drug should be discontinued. Large bowel endoscopy should be considered to establish a definitive diagnosis in cases of severe diarrhea.
Antiperistaltic agents, such as opiates and diphenoxylate with atropine, may prolong and/or worsen the condition. Diarrhea, colitis, and pseudomembranous colitis have been observed to begin up to several weeks following cessation of oral and parenteral therapy with clindamycin.
🤒 Adverse Reactions ▾
ADVERSE REACTIONS In the one well-controlled clinical study comparing Clindamycin Phosphate Topical Gel and its vehicle, the incidence of skin and appendages adverse events occurring in ≥1% of the patients in either group is presented in the following table: Number (%) of Patients Body System/Adverse Event Clindamycin Phosphate Topical Gel QD N=168 Vehicle Gel QD N=84 Skin and Appendages Disorders • Dermatitis 0 (0.0) 1 (1.2) • Dermatitis contact 0 (0.0) 1 (1.2) • Dermatitis fungal 0 (0.0) 1 (1.2) • Folliculitis 0 (0.0) 1 (1.2) • Photosensitivity reaction 0 (0.0) 1 (1.2) • Pruritus 1 (0.6) 1 (1.2) • Rash erythematous 0 (0.0) 0 (0.0) • Skin dry 0 (0.0) 0 (0.0) • Peeling 1 (0.6) 0 (0.0) Orally and parenterally administered clindamycin has been associated with severe colitis, which may end fatally.
Cases of diarrhea, bloody diarrhea, and colitis (including pseudomembranous colitis) have been reported as adverse reactions in patients treated with oral and parenteral formulations of clindamycin and rarely with topical clindamycin (see WARNINGS ). Abdominal pain and gastrointestinal disturbances, as well as gram-negative folliculitis, have also been reported in association with the use of topical formulations of clindamycin. To report SUSPECTED ADVERSE REACTIONS, contact Oceanside Pharmaceuticals at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
🆘 Overdosage ▾
OVERDOSAGE Topically applied Clindamycin Phosphate Topical Gel may be absorbed in sufficient amounts to produce systemic effects (see WARNINGS ).
🧬 Clinical Pharmacology ▾
CLINICAL PHARMACOLOGY Pharmacokinetics: In an open-label, parallel group study of 24 patients with acne vulgaris, once-daily topical administration of approximately 3 to 12 grams/day of Clindamycin Phosphate Topical Gel for 5 days resulted in peak plasma clindamycin concentrations that were less than 5.5 ng/mL. Following multiple applications of Clindamycin Phosphate Topical Gel less than 0.04% of the total dose was excreted in the urine. Microbiology: Although clindamycin phosphate is inactive in vitro, rapid in vitro hydrolysis converts this compound to clindamycin, which has antibacterial activity.
Clindamycin inhibits bacteria protein synthesis at the ribosomal level by binding to the 50S ribosomal subunit and affecting the process of peptide chain initiation. In vitro studies indicated that clindamycin inhibited all tested Propionibacterium acnes cultures at a minimum inhibitory concentration (MIC) of 0.4 mcg/mL. Cross-resistance has been demonstrated between clindamycin and erythromycin.
📦 How Supplied / Storage and Handling ▾
HOW SUPPLIED Clindamycin Phosphate Topical Gel containing clindamycin phosphate equivalent to 10 mg clindamycin per gram is available in the following size: 75 mL bottle - NDC 68682-462-75 Store at controlled room temperature 20°to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F). Do not store in direct sunlight. Retain in carton until contents are used.
Distributed by: Oceanside Pharmaceuticals, a division of Bausch Health US, LLC Bridgewater, NJ 08807 USA Manufactured by: Bausch Health Companies Inc. Laval, Quebec H7L 4A8, Canada © 2020 Bausch Health Companies Inc. or its affiliates 9706400 Rev. 01/20
📋 Description ▾
DESCRIPTION Clindamycin Phosphate Topical Gel, 1%, a topical antibiotic, contains clindamycin phosphate, USP, at a concentration equivalent to 10 mg clindamycin per gram in a gel vehicle consisting of carbomer 941, methylparaben, polyethylene glycol 400, propylene glycol, purified water, and sodium hydroxide. Chemically, clindamycin phosphate is a water-soluble ester of the semi-synthetic antibiotic produced by a 7 (S)-chlorosubstitution of the 7 (R)-hydroxyl group of the parent antibiotic, lincomycin, and has the structural formula represented below: The chemical name for clindamycin phosphate is methyl 7-chloro-6,7,8-trideoxy-6-(1-methyl- trans -4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-L- threo -α-D- galacto -octopyranoside 2-(dihydrogen phosphate). clindagel-01